# Sagimet Biosciences Inc. (SGMT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $68M  
**Price:** $6.50 (-0.31%)

> Sagimet Biosciences Inc. is a biotechnology company focused on the development of therapeutics targeting critical metabolic pathways in fibrotic diseases and cancer. The company's primary function is to leverage its proprietary platform to discover and develop small molecule drugs that can modulate key biological receptors implicated in disease progression. Sagimet's pipeline includes lead programs aimed at treating diseases such as nonalcoholic steatohepatitis (NASH) and certain forms of cancer, addressing significant unmet medical needs. By targeting specific metabolic enzymes, the company seeks to provide innovative treatment options that could potentially improve patient outcomes in these challenging and prevalent conditions. Sagimet Biosciences plays a crucial role in the healthcare and life sciences sectors, distinguishing itself with a focus on precision medicine and first-in-class therapeutics. This strategic approach positions the company as a significant player in the field of novel drug discovery and development within the broader pharmaceutical industry.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2023 | $2M | — | -$31M | -$28M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2023 | $97M | $6M | $91M | $75M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$46M | — | — |
| 2024 | -$42M | — | — |
| 2023 | -$24M | — | — |
| 2022 | -$24M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/SGMT)